Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1701461

registered interest
date	16/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Diabetes: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether she is working with her international counterparts to tackle supply issues relating to (a) semaglutide and (b) other glucagon-like peptide-1 receptor agonists licensed for treating patients with type 2 diabetes.
tabling member constituency	West Lancashire
tabling member printed	Ashley Dalton
uin	22203
answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>The Department has worked intensively with industry to seek commitments from them to address issues with the supply of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), including semaglutide, to expedite deliveries and boost supplies. As a result, the overall supply position in the United Kingdom has improved. Guidance for healthcare professionals now allows for the initiation of new patients on Rybelsus tablets, an oral semaglutide, and provides advice on what to prescribe patients who are unable to obtain their existing GLP-1 RA treatment whilst there continue to be disruptions to the supply of some products, including semaglutide. These disruptions are affecting many countries around the world, and aren’t specific to the UK.</p><p>We continue to work with international partners, given the global nature of medical supply chains, collaborating to share best practice and manage and respond to common threats to supply, including on semaglutide and other GLP-1 RAs licensed for treating patients with type 2 diabetes.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 22201 22202 question first answered 22/04/2024 09:40:27 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4981 label Biography information for Ashley Dalton

1689527

registered interest
date	16/02/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Diabetes: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps her Department is taking to help stop disruption of the supply of (a) Ozempic, (b) Trulicity and (c) similar medicines.
tabling member constituency	Leeds North West
tabling member printed	Alex Sobel
uin	14426
answer	answer is ministerial correction date of answer 21/02/2024 answer text <p>While the position has improved, there continues to be a global supply issue with glucagon-like peptide-1 receptor agonists (GLP-1 RA), including Trulicity (dulaglutide) and Ozempic (semaglutide). We have issued updated guidance to healthcare professionals in the form of a National Patient Safety Alert on the 3 January 2024, on how to manage patients requiring these medicines.</p><p>Our guidance is clear that GLP-1 RAs that are solely licensed to treat type 2 diabetes should only be used for that purpose, and should not be routinely prescribed for weight loss. The General Pharmaceutical Council, General Medical Council, Health and Care Professions Council, Nursing and Midwifery Council and the Pharmaceutical Society of Northern Ireland have also issued a joint statement stressing the importance of health and care professionals meeting regulatory standards in relation to these medicines.</p><p>We know how distressing and frustrating medicine supply issues can be, and the Department will continue to help in ensuring that these critical medicines reach diabetes patients. If any patient is concerned about their treatment, they should discuss this with their clinician at the earliest opportunity.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 14424 14425 question first answered 21/02/2024 16:10:45 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4658 label Biography information for Alex Sobel

1687858

registered interest
date	06/02/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Diabetes: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps her Department is taking to (a) monitor the availability, (b) notify relevant stakeholders of shortages and (c) help ensure adequate supply of (i) Victoza and (ii) other medications for patients with diabetes.
tabling member constituency	Brighton, Pavilion
tabling member printed	Caroline Lucas
uin	13302
answer	answer is ministerial correction date of answer 13/02/2024 answer text <p>We are aware of global supply issues with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) including Victoza (liraglutide), which are licensed for treating patients with type 2 diabetes. We have issued guidance in the form of a Medicine Supply Notification, addressing all GLP-1 RAs advising healthcare professionals on how to manage patients requiring these medicines. Further guidance has been issued through a National Patient Safety Alert which provides further background and clinical information and actions for providers. This guidance was futher updated on 3 January 2024.</p><p>Our guidance is clear that GLP-1 RA medicines that are solely licensed to treat type 2 diabetes should only be used for that purpose and should not be routinely prescribed for weight loss.</p><p>The General Pharmaceutical Council, General Medical Council, Health and Care Professions Council, Nursing and Midwifery Council and Pharmaceutical Society of Northern Ireland have also issued a joint statement stressing the importance of health and care professionals meeting regulatory standards in relation to these medicines. We have also added some of these products to the list of medicines that cannot be exported from, or hoarded in, the United Kingdom.</p><p>We are continuing to work closely with manufacturers and others working in the supply chain to help ensure the continued supply of these medicines for UK patients, for example by asking suppliers to expedite deliveries. Supplies of Rybelsus (semaglutide) have been boosted to support demand from new patients with type 2 diabetes, alongside patients switching from Victoza injections.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 13/02/2024 17:54:36 answering member 4044 label Biography information for Andrew Stephenson
tabling member	3930 label Biography information for Caroline Lucas

1684187

registered interest
date	22/01/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Diabetes: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask Secretary of State for Health and Social Care, what estimate she has made of the number of people with type 2 diabetes impacted by the GLP-1 shortage.
tabling member constituency	Darlington
tabling member printed	Peter Gibson
uin	10916
answer	answer is ministerial correction date of answer 29/01/2024 answer text <p>Information on the number of people impacted by the glucagon-like peptide 1 (GLP-1) shortage is not held by the Department. There continues to be a global supply issue with some GLP-1 receptor agonists, but following the Department’s ongoing engagement with manufacturers, NHS England, the Medicines and Healthcare products Regulatory Agency and others operating in the supply chain, the overall supply position has improved, with additional stock being secured to boost availability of these medicines for patients.</p><p>We issued updated guidance to healthcare professionals, in the form of a National Patient Safety Alert, on 3 January 2024. This provides advice on how to manage patients requiring these medicines. Our guidance remains clear that GLP-1 receptor agonists that are solely licensed to treat type 2 diabetes should only be used for that purpose and should not be prescribed for weight loss.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 29/01/2024 16:02:14 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4754 label Biography information for Peter Gibson

1667631

registered interest
date	07/11/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Diabetes: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of the supply of Ozempic pens for patients with type 2 diabetes.
tabling member constituency	Brentford and Isleworth
tabling member printed	Ruth Cadbury
uin	242
answer	answer is ministerial correction date of answer 17/11/2023 answer text <p>We are aware of a supply issue with glucagon-like peptide 1 receptor agonist (GLP-1 RA) medicines, including Ozempic pens. We have issued guidance in the form of Medicine Supply Notifications and, on 18 July 2023, issued a National Patient Safety Alert with advice for healthcare professionals on how to manage patients requiring this medicine.</p><p>Our guidance is clear that GLP-1 RA medicines that are solely licensed to treat Type 2 diabetes should only be used for that purpose and should not be routinely prescribed for weight loss.</p><p>The General Pharmaceutical Council, General Medical Council, Health and Care Professions Council, Nursing and Midwifery Council and Pharmaceutical Society of Northern Ireland have also issued a joint statement stressing the importance of health and care professionals meeting regulatory standards in relation to these medicines. We have also added some of these products to the list of medicines that cannot be exported from, or hoarded in, the United Kingdom.</p><p>We are continuing to work closely with manufacturers and others working in the supply chain to help ensure the continued supply of these medicines for UK patients, for example by asking suppliers to expedite deliveries. We have provided advice for healthcare professionals on how to manage patients requiring this medicine whilst there are shortages and are keeping this under review as the situation evolves.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 243 question first answered 17/11/2023 12:35:15 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4389 label Biography information for Ruth Cadbury

1666738

registered interest
date	23/10/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Diabetes: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what recent steps he has taken mitigate the impact of shortages of (a) Ozempic, (b) Rybelsus, (c) Trulicity, (d) Victoza, (e) Saxenda, (f) Byetta and (g) Bydureon.
tabling member constituency	Birmingham, Edgbaston
tabling member printed	Preet Kaur Gill
uin	203902
answer	answer is ministerial correction date of answer 26/10/2023 answer text <p>We are aware of a supply issue with GLP-1 RA medicines. This includes Ozempic, Rybelsus, Trulicity, Victoza, Saxenda, Byetta and Bydureon. We have issued guidance in the form of Medicine Supply Notifications and, on 18 July 2023, issued a National Patient Safety Alert with advice for healthcare professionals on how to manage patients requiring this medicine.</p><p>Our guidance is clear that GLP-1 RA medicines that are solely licensed to treat Type 2 diabetes should only be used for that purpose and should not be routinely prescribed for weight loss.</p><p>The General Pharmaceutical Council, General Medical Council, Health and Care Professions Council, Nursing and Midwifery Council and Pharmaceutical Society of Northern Ireland have also issued a joint statement stressing the importance of health and care professionals meeting regulatory standards in relation to these medicines. We have also added some of these products to the list of medicines that cannot be exported from, or hoarded in, the United Kingdom.</p><p>We are continuing to work closely with manufacturers and others working in the supply chain to help ensure the continued supply of these medicines for UK patients, for example by asking suppliers to expedite deliveries. We have provided advice for healthcare professionals on how to manage patients requiring this medicine while there are shortages and are keeping this under review as the situation evolves.</p> answering member constituency Colchester answering member printed Will Quince question first answered 26/10/2023 08:37:24 answering member 4423 label Biography information for Will Quince
tabling member	4603 label Biography information for Preet Kaur Gill

1661136

registered interest
date	18/09/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Diabetes: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether he plans to undertake a review of guidance on the prescription of glucagon-like peptide 1 (GLP-1) agonists to patients with type 2 diabetes.
tabling member constituency	Slough
tabling member printed	Mr Tanmanjeet Singh Dhesi
uin	200010
answer	answer is ministerial correction date of answer 16/10/2023 answer text <p>The National Institute for Health and Care Excellence (NICE) is the independent body responsible for providing evidence-based guidance for the National Health Service in England, in line with its established methods and processes.</p><p>NICE’s guideline on the management of type 2 diabetes in adults states that if triple therapy with metformin and 2 other oral drugs is not effective, not tolerated or contraindicated, switching one drug for a glucagon-like peptide 1 agonist should be considered for people who meet the specified criteria.</p><p>NICE is currently updating the drug treatment section of this guideline, which it expects to publish in December 2024. NICE also published final draft guidance on 8 September 2023 which recommends tirzepatide for treating type 2 diabetes alongside diet and exercise in adults who meet the specified criteria. Final guidance on tirzepatide is expected in October 2023.</p> answering member constituency Colchester answering member printed Will Quince question first answered 16/10/2023 13:29:48 answering member 4423 label Biography information for Will Quince
tabling member	4638 label Biography information for Mr Tanmanjeet Singh Dhesi

1660994

registered interest
date	15/09/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Diabetes: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what discussions he has had with international counterparts on addressing shortages medicines to treat type 2 diabetes.
tabling member constituency	Slough
tabling member printed	Mr Tanmanjeet Singh Dhesi
uin	199819
answer	answer is ministerial correction date of answer 21/09/2023 answer text <p>The Department has established processes to manage disruption to medical products and protect patient care. Supply chains for medical products are complex, global, and highly regulated, making them vulnerable to a variety of shocks, including around manufacture failure, demand spikes, international trade activity and disruption to logistics. In this specific case of medicines to treat type 2 diabetes, we are aware of a global supply issue with glucagon-like peptide-1 receptor agonists which are licensed for treating patients with type 2 diabetes. Whilst no specific discussions have been had with international counterparts, we are committed to working with international partners on the broader supply agenda.</p><p>We are continuing to work closely with manufacturers of medicines to treat type 2 diabetes and others working in the supply chain to help ensure the continued supply for patients in the United Kingdom, for example by asking suppliers to expedite deliveries. Alongside, we have provided advice for healthcare professionals on how to manage patients requiring these medicines whilst there are in shortage and are keeping this under review as the situation evolves. If any patient is concerned about their treatment, they should discuss this with their clinician at the earliest opportunity.</p> answering member constituency Colchester answering member printed Will Quince question first answered 21/09/2023 09:31:49 answering member 4423 label Biography information for Will Quince
tabling member	4638 label Biography information for Mr Tanmanjeet Singh Dhesi

1660728

registered interest
date	14/09/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Diabetes: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what recent estimate he has made of the number and proportion of people with type 2 diabetes who will be affected by the shortage of GLP1-RA medications.
tabling member constituency	Slough
tabling member printed	Mr Tanmanjeet Singh Dhesi
uin	199596
answer	answer is ministerial correction date of answer 19/09/2023 answer text <p>The information requested is currently not held centrally. The Department is monitoring demand for GLP1-RA medication using prescriptions data from the NHS Business Services Authority.</p> answering member constituency Colchester answering member printed Will Quince question first answered 19/09/2023 15:57:51 answering member 4423 label Biography information for Will Quince
tabling member	4638 label Biography information for Mr Tanmanjeet Singh Dhesi

1660807

registered interest
date	14/09/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Diabetes: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to increase stocks of diabetes medication.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Paula Barker
uin	199678
answer	answer is ministerial correction date of answer 19/09/2023 answer text <p>We are aware of a supply issue with Ozempic. We have issued guidance in the form of Medicine Supply Notifications and, on 18 July 2023, issued a National Patient Safety Alert with advice for healthcare professionals on how to manage patients requiring this medicine. Our guidance is clear that glucagon-like peptide 1 receptor agonist medicines, such as Ozempic, that are solely licensed to treat Type 2 diabetes should only be used for that purpose and should not be routinely prescribed for weight loss.</p><p>The General Pharmaceutical Council, General Medical Council, Health and Care Professions Council, Nursing and Midwifery Council and Pharmaceutical Society of Northern Ireland have also issued a joint statement stressing the importance of health and care professionals meeting regulatory standards in relation to these medicines. We have also added some of these products to the list of medicines that cannot be exported from, or hoarded in, the United Kingdom.</p><p>We are continuing to work closely with manufacturers and others working in the supply chain to help ensure the continued supply of these medicines for patients in the UK, for example by asking suppliers to expedite deliveries. We have provided advice for healthcare professionals on how to manage patients requiring this medicine whilst there are shortages and are keeping this under review as the situation evolves. If any patient is concerned about their treatment, they should discuss this with their clinician at the earliest opportunity.</p> answering member constituency Colchester answering member printed Will Quince grouped question UIN 199679 question first answered 19/09/2023 09:35:57 answering member 4423 label Biography information for Will Quince
tabling member	4828 label Biography information for Paula Barker